Sartorius to add flagship site in North America
The company plans to open a new 130,000-sq. ft plant in Ann Arbor in late 2023
German laboratory and pharmaceutical equipment provider, Sartorius, has announced plans to expand its presence in Michigan by opening a new 130,000-sq. ft (12,000-m2) state-of-the art plant in the Tech Loop, at the Ann Arbor Research Park in late 2023.
The moves comes as demand for innovative technologies used in developing and producing biopharmaceuticals continues to grow rapidly.
The new plant will focus on providing innovative solutions to help customers develop drugs that cure, prevent, and halt the progression of diseases.
The 15 acres of land the company has already purchased for its new flagship site will provide sufficient space for further expansion. By 2025, Sartorius anticipates it will more than double capacities for its key product groups.
Sartorius, which has 22 production sites worldwide, has said the new site is an integral part of its ongoing worldwide expansion, which will enable it to scale up its operations and capabilities in the Ann Arbor biotech hub. By 2025, Sartorius will more than double capacities for its key product groups.
The project is expected to create 160 jobs, including product development, operations, and other support functions, over 3 years.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.